Key Event Components

Key Event Components (KECs) are used to describe Key Events (KEs) in a computable way, by defining an action, processes, and object term that maps to controlled vocabulary and ontology terms.
KECs on this page can be filtered by the action, process, and object terms, as well as by source ontologies.
Link to source ontology terms are provided in cases where the URL was available when the ontology terms were added to the AOP-Wiki database.
A complete list of all KECs is available in TSV format on the Downloads Page.

Showing 1101 to 1125 of 1146 KECs

ID	Action	Process	Object	Associated Key Events (KEs)


619	increased		cough (MESH:D003371)	2 Events 1223: Trigeminal and/or vagal nerve excitation causes Airway Hyper-responsiveness,Cough, Dyspnea 1226: Increased Respiratory irritability and Chronic Cough,
765	increased	response to reactive oxygen species (GO:0000302)	reactive oxygen species (CHEBI:26523)	2 Events 1869: Diminished protective oxidative stress response 1753: Chronic reactive oxygen species
860	increased	DNA damage response, detection of DNA damage (GO:0042769)	site of DNA damage (GO:0090734)	2 Events 2006: Secondary genotoxicity 1669: Increased, DNA damage and mutation
862	increased	chromosome breakage (GO:0031052)	chromosome (GO:0005694)	2 Events 1669: Increased, DNA damage and mutation 1636: Increase, Chromosomal aberrations
863	increased	chromosomal instability (MP:0008866)	chromosome (GO:0005694)	2 Events 1669: Increased, DNA damage and mutation 1896: Genomic instability
887	increased	gene expression (GO:0010467)		2 Events 2021: Increase, slincR expression 2199: Increased, Expression of LXR activated genes
888	decreased	gene expression (GO:0010467)		2 Events 2020: Decrease, sox9 expression 2214: Decreased, Insulin-like peptide 3 (INSL3)
943	increased	acute-phase response (GO:0006953)	Acute phase proteins (N/A)	2 Events 1438: Transcription of genes encoding acute phase proteins, Increased 1439: Systemic acute phase response
996	increased	demyelination (MP:0000921)		2 Events 2098: Increase, Abnormal Neural Remodeling 2266: Demyelination, increased
998	increased	cell surface receptor signaling pathway (GO:0007166)		2 Events 2244: Altered Stress Response Signaling 2245: Altered Cell Differentiation Signaling
1107	increased	Metaplasia (MESH:D008679)	Squamous cell (FMA:66769)	2 Events 1068: Endometrial squamous metaplasia, Increase 2372: Squamous metaplasia, Increase
1	increased	cell proliferation (GO:0008283)		3 Events 57: Proliferation, Cell proliferation in the absence of cytotoxicity 416: Increase proliferation, Leydig cell 1182: Increase, Cell Proliferation (Epithelial Cells)
2	increased	hyperplasia (MESH:D006965)		3 Events 142: Hyperplasia, Hyperplasia 415: Hyperplasia, Leydig cell 1192: Increased, Ductal Hyperplasia
32	decreased	aromatase activity (GO:0070330)	aromatase (PR:000006100)	3 Events 408: reduction in ovarian granulosa cells, Aromatase (Cyp19a1) 36: Inhibition, Aromatase 800: Decreased, Aromatase (Cyp19a1) mRNA
41	decreased		thyroxine (CHEBI:30660)	3 Events 771: Decrease, Serum thyroid hormone (T4/T3) 1022: Decreased, serum T4/T3 1093: Decreased, Thyroxine (T4) in tissues
65	increased	glucocorticoid receptor activity (GO:0004883)	glucocorticoid receptor (PR:000011406)	3 Events 122: Increase, Glucocorticoid receptor activation 494: Glucocorticoid Receptor Agonist, Activation 654: Decreased testosterone by the fetal Leydig cells, Activation by other glucocorticoid receptor agonists
73	increased	mutation (MESH:D009154)	deoxyribonucleic acid (CHEBI:16991)	3 Events 185: Increase, Mutations 336: Increase, Heritable mutations in offspring 876: Increase, Mutations in Critical Genes
80	increased	ataxia (MP:0001393)		3 Events 39: Increased Cholinergic Signaling 602: Increased, Ataxia, paralysis, or hyperactivity 764: N/A, Ataxia, paralysis, or hyperactivity
81	increased	hyperactivity (MP:0001399)		3 Events 39: Increased Cholinergic Signaling 602: Increased, Ataxia, paralysis, or hyperactivity 764: N/A, Ataxia, paralysis, or hyperactivity
123	increased	oxidative stress (MP:0003674)		3 Events 209: Peptide Oxidation 1279: Increase, Oxidative Stress / Activation, PMK-1 P38 MAPK 1392: Increase, Oxidative Stress
137	increased	estrogen receptor activity (GO:0030284)	estrogen receptor (PR:000007204)	3 Events 111: Agonism, Estrogen receptor 659: Decreased testosterone by the fetal Leydig cells, Activation by other estradiol agonists 748: Increased, Estrogen receptor (ER) activity
163	increased		hepatocellular carcinoma (MESH:D006528)	3 Events 347: Formation, Liver tumor 856: Formation, Hepatocellular and Bile duct tumors 378: Tumorigenesis, Hepatocellular carcinoma
172	increased	SREBP signaling pathway (GO:0032933)	sterol regulatory element-binding protein 1 (PR:000015611)	3 Events 264: Activation, SREBP-1c 878: Inhibition, SREBP1c 457: Activation, SREBF1
181	decreased	peroxisome proliferator activated receptor signaling pathway (GO:0035357)	peroxisome proliferator-activated receptor alpha (PR:000013056)	3 Events 231: Decreased, PPAR-alpha activation 468: Inhibition, PPAR alpha 1057: Increased, PPAR-alpha activation
201	increased	cell activation (GO:0001775)		3 Events 398: Activation, Dendritic Cells 650: Stimulation of adult Leydig cells via the Adrenal Corticosterone, Increased Glucocorticoid 981: Reduction, NFAT/AP-1 complex formation